ABSTRACT
Gram-positive cocci, including enterococci and Staphylococcus aureus, have become the leading cause of hospital-acquired infections, and their resistance to antibiotics is increasing.Two important new drugs—quinupristin/dalfopristin (Synercid) and linezolid (Zyvox)—were designed specifically to treat infections due to drug-resistant gram-positive cocci. But their use must be tempered by their cost, toxicity, and concerns about further development of resistant strains.
Footnotes
↵* The author has indicated that she has received grant or research support from the Aventis corporation and serves as a consultant and is on the speakers’ bureaus of the Pharmacia and Aventis corporations.
- Copyright © 2002 The Cleveland Clinic Foundation. All Rights Reserved.